James A Simon MD PC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$7,787	4
2024	Research	$3,980	3
2023	Research	$24,101	11
2022	Research	$27,930	7
2021	Research	$4,055	4
2019	Research	$3,992	4

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $61,075 24 payments
Myovant Sciences Inc. $4,055 4 payments
AMAG Pharmaceuticals, Inc. $3,992 4 payments
Sumitomo Pharma America, Inc. $2,723 1 payment

Studies the money was for Research payments · program years 2019–2025

Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $27,930 7 payments
Long-Term Safety Study of Elagolix in Combination With Estradiol;Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $21,378 10 payments
M16-283 - Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $7,787 4 payments
Spirit Extension: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $4,055 4 payments
Prasterone DHEA for the Treatment of Hypoactive Sexual Desire Disorder HSDD - Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone $3,992 4 payments
Spirit Extension: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $2,723 1 payment
Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $2,525 2 payments
Long-Term Safety Study of Elagolix in Combination With Estradiol Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women $1,455 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.